CCL5 and ductal breast carcinoma in situ: In the group of IDC-with-relapse patients, the incidence of CCL2 & CCL5 expression was similarly high to that of DCIS and IDC-no-relapse group (50-65%), while that of TNFα & IL-1β has reached about 85-90%.